Lttl review

What it is

Lttl (pronounced "little") is a direct-to-consumer telehealth brand owned and operated by The Commerce Group Holdings, LLC. Its weight-loss line covers compounded semaglutide and tirzepatide as injectables, an oral dissolving-tablet semaglutide, and a microdose line for both molecules. Its longevity line covers sermorelin, glutathione, methylene blue, MIC B12, L-carnitine, and NAD⁺ in three forms — injectable, nasal spray and oral liposomal liquid. Clinical services are delivered by independent networks of US-licensed clinicians, and it bills one flat rate regardless of dose.

How it works

Asynchronous and storefront-led, with an unusual amount published up front. Its plans page lays out every product against every commitment tier, its inclusions are itemised — an asynchronous medical assessment reviewed by a US-licensed provider, ongoing access to a care team, medication dispensed and shipped by a partner US pharmacy, cold-chain shipping with tracking where required — and flat dose pricing is stated verbatim as "same price at every dose", so a dose increase does not raise the bill. It also states, more explicitly than most, that its compounded GLP-1s are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality. Against that sit several things worth flagging. No partner pharmacy is named anywhere — the terms refer only to "Partner Pharmacies" — and no state list is published. A site banner promises prescription and shipping within 48 hours while the shipping policy states two to five business days to process plus three to seven to deliver. The footer links to LegitScript, but that link resolves to a generic lookup form with no certification record for the domain, which is not the same as being certified. And the terms impose mandatory individual arbitration with a class-action waiver.

Pricing transparency

This is the most complete matrix in the batch and it rewards reading. Sermorelin, glutathione, methylene blue, MIC B12 and L-carnitine are each $119 a month month-to-month, $99 a month on a three-month prepay, $89 on six months and $79 on twelve. NAD⁺ — injectable, nasal spray or oral liquid — sits on its own ladder at $199 a month month-to-month, $169 on three months, $149 on six and $129 on twelve. The number to budget against is the month-to-month one, because the lower tiers require paying the whole term up front. That is the same structure Lttl runs on GLP-1s, where the advertised "plans start at $129/mo" is the twelve-month prepay against a true month-to-month rate of $199 for semaglutide and $279 for tirzepatide. Flat dose pricing is a real advantage across all of it: your bill does not rise when the dose does. Cancellation is available anytime on the monthly plan with a full refund if a provider finds you medically ineligible at the initial consultation, but medication is non-returnable and non-refundable once the pharmacy ships it.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Lttl's own FAQ is unusually blunt — its compounded products are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality — and it does not name the partner pharmacy, so compounded sterile products carry the usual caveat that the FDA does not review them for purity and potency. On evidence the longevity ladder is a mix. Sermorelin is a GHRH analogue that stimulates your own pituitary; the mechanism is real and well described, and the long-term human outcome data is thin. NAD⁺ deserves particular care here because Lttl sells three routes: injected, intranasal and oral liposomal NAD⁺ all lack controlled human outcome trials, and the intranasal and liposomal routes have the weakest pharmacokinetic support of the three — the NAD⁺ forms with human trial data are the oral precursors NR and NMN, and what those trials show is a raised blood NAD⁺ level rather than a clinical benefit. Injectable glutathione has essentially no controlled human outcome data. Methylene blue is a genuinely approved drug for methaemoglobinaemia being sold here for cognitive and mitochondrial claims that have no controlled human outcome trials behind them, and it interacts seriously with serotonergic medications including SSRIs — a question to raise explicitly at intake. Individual results vary.

Pros and watch-outs

The evidence behind what Lttl prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

How Lttl compares

A few alternatives worth a look, depending on what you’re optimizing for.

• KOKongo

  NAD⁺ injections at a published flat rate across all 50 states

  See Kongo →
• LILiberty

  NAD⁺ from a platform that sources through 503B outsourcing facilities nationwide

  See Liberty →
• LRLevelUp Rx

  NAD⁺ injections from a platform that names the pharmacies dispensing them

  See LevelUp Rx →